For sure, I think it is an interesting proposal that could really increase harmonization in regulations. That's a huge cost for a lot of generic drug companies, dealing with multiple regulatory barriers, paperwork, red tape and stuff. Crossing that can be quite a cost.
On May 25th, 2021. See this statement in context.